Skip to content
Timeline: Our Key Moments of 2022
Our Key Moments in 2022:
- Dr. Rodica Pop-Busui is named President-elect of the American Diabetes Association.
- Dr. Eva Feldman becomes the first female recipient of the Robert S. Schwab Award.
- We identify pathways in ALS that shed light on ALS mechanisms and therapeutic targets.
- We oversee a special issue of Neurobiology of Disease focused on brain health.
- We publish updated guidelines for the diagnosis and treatment of diabetic neuropathy.
- We show that a repurposed FDA-approved drug has major potential as a therapeutic strategy for ALS.
- We host a NeuroNetwork Mini Symposium:“Protecting Your Brain from Stress” with the Eisenberg Family Depression Center.
- Drs. Sarah Elzinga and Evan Reynolds receive K99 Pathway to Independence Awards from the National Institutes of Health (NIH).
- We report that specific plasma lipids identify neuropathy risk in obesity.
- Dr. Kevin Chen is named the next Handleman Emerging Scholar.
- Dr. Stephen Goutman and the Pranger ALS Clinic team attend the StrikeOut ALS U-M baseball game and ALS Box Car Derby.
- Our two ALS reviews are featured on the cover of Lancet Neurology’s 20th Anniversary issue.
- Dr. Ben Murdock becomes the first Robert A. Epstein & Joan M. Chernoff-Epstein Emerging Scholar.
- Andi and Larry Wolfe fund the Wolfe Wellness Initiative for Brain Health and a research professorship.
- New undergraduates join the lab for the summer as Tauber Student Interns.
- Dr. Kevin Chen is awarded a grant from the Alzheimer’s Association to examine the mechanisms of the disease.
- Dr. Feldman is named the James W. Albers Distinguished University Professor, one of U-M’s highest honors. Dr. Albers is a longtime mentor who was instrumental in her early career.
- The NIH awards us an R01 grant to examine mechanisms underlying dietary interventions for neuropathy.
- We report that the levels of types of fat in the blood are associated with future development of neuropathy in type 2 diabetes, and that a high-fat diet can impact nerve health in mice.
- Dr. Feldman publishes a prestigious ALS Seminar article in Lancet.
- NeuroNetwork MD/PhD student Rosie Henn successfully defends her dissertation and earns her Ph.D.
- We received a new grant from the CDC to further study mechanisms underlying ALS, related to the immune system.
- We publish an optimized approach to support long-term survival of stem cell transplants in the brain, which can be important for future clinical trials of stem cell therapies for Alzheimer’s disease.
- Dr. Eva Feldman presents at the Presidential Symposium of both the American Academy of Neurology (AAN) and American Neurological Association (ANA).
- NeuroNetwork investigators present at the final session of the 6-year International Diabetic Neuropathy Consortium in Denmark.
- We identify microRNAs in blood and skin cells from ALS subjects that could be leveraged to improve ALS diagnosis and treatment options.
- We show work in production occupations is associated with increased ALS risk. This gets a front-page feature in the Detroit Free Press.
- We host a NeuroNetwork Mini Symposium entitled “A Youth Mental Health Crisis: The Surge After the Surge.”
- Dr. Stephanie Eid is awarded the ANA’s Wolfe Research Prize for Identifying New Causes or Novel Treatments of Neuropathy.
- Dr. Feldman shares ALS research advances associated with our NIH Director’s Transformative Research Award at the NIH High-Risk, High-Reward research seminar.
- The Eva L. Feldman MD, PhD, Professorship is established with a gift from Edie Briskin—Dr. Brian Callaghan becomes the inaugural Feldman Professor of Neurology.
- The CDC visits our group to discuss our ALS research progress under ongoing and new CDC grants.
- Dr. Feldman visits our Australian collaborators as part of our NIH-funded Cognition and Longitudinal Assessment of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study.